Controversy in treatment of advanced ovarian cancer

Affiliations

Comment

Giovanni Scambia et al. Lancet Oncol. 2013 Sep.

. 2013 Sep;14(10):920-1.

doi: 10.1016/S1470-2045(13)70391-7.

¹ Catholic University of the Sacred Heart of Rome, Largo Agostino Gemelli 1, 00168 Rome, Italy. giovanni.scambia@rm.unicatt.it

No abstract available

Comment on

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Lancet Oncol. 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948349 Clinical Trial.